Laferomax suppositories 3000000 MO 1g. №10

Description

Laferomax 3000000 Composition

active substance: interferon alfa-2b1 suppository contains: recombinant human interferon alfa-2b – 1,000,000 IU or 3,000,000 IU
excipients: tocopherol acetate 5% oily solution, ascorbic acid, solid fat.

Laferomax 3000000 Dosage form

Suppositories

Basic physical and chemical properties

suppositories of spherical shape of yellowish-white color of uniform consistency.

Laferomax 3000000 Pharmacological group

Immunostimulants. Interferon alpha-2b. ATX code L03A B05.

Laferomax 3000000 Pharmacological properties

Interferon alfa-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulatory effect. The complex composition of Laferomax causes a number of new effects: in combination with tocopherol acetate and ascorbic acid, the antiviral activity of recombinant interferon alpha-2b increases 10-14 times, its immunomodulatory effect on T- and B-lymphocytes increases, the content of immunoglobulin E is normalized. Antibodies are not formed , neutralizing the antiviral activity of recombinant interferon alfa-2b, even when used for 2 years, the functioning of the endogenous system is normalized.

Indications

For adults:

with papillomavirus infection (vulgar warts, genital warts)
with urogenital mixed sexually transmitted infections
with precancerous diseases of the cervix.
Contraindications

Hypersensitivity to the components of the drug the presence of thyroid dysfunction in the patient the presence of severe visceral disorders in patients with Kaposi’s sarcoma severe cardiovascular diseases psoriasis severe liver and / or kidney dysfunction epilepsy and other diseases of the central nervous system (including functional) chronic hepatitis on background of progressive or decompensated cirrhosis of the liver, chronic hepatitis in patients receiving or recently received immunosuppressive therapy (except for a short course of corticosteroids), autoimmune hepatitis or other autoimmune diseases in history. Inhibition of the myeloid germ of hematopoiesis.

Interaction with other medicinal products and other types of interactions

The drug should be used with caution in conjunction with opioid drugs, analgesics, hypnotics and sedatives (potentially causing a myelosuppressive effect).

Application features

Treatment with Laferomax should be carried out under the supervision of a physician.

Before prescribing the drug for a long time, it is recommended to study the function of the thyroid gland. The drug should be started on the condition that the level of thyroid-stimulating hormone (TSH) is within the normal range. If any changes in the level of thyroid-stimulating hormone are found, appropriate therapy should be carried out and therapy with Laferomax should be started, provided that the content of thyroid-stimulating hormone can be maintained at a normal level. In the course of treatment, it is also advisable to control the level of thyroid-stimulating hormone.